Overload

Sequana Medical announces Annual General Meeting of Shareholders on 25 May 2023

Retrieved on: 
星期二, 四月 23, 2024
Annual, Cancer, International, Partner, Liver disease, EUR, Brussels Stock Exchange, Convertible, European, Overload, Transaction, Committee, Annual report, Heart failure, Security (finance)

The annual report for the financial year 2023 has been published on Sequana Medical's website and can be accessed here .

Key Points: 
  • The annual report for the financial year 2023 has been published on Sequana Medical's website and can be accessed here .
  • The Annual and Extraordinary General Meetings of Shareholders will take place at the Company's registered offices in Ghent and will start at 09:00 am CET.
  • The full convening notice with the agenda and proposed resolutions can be accessed on the Sequana Medical website: www.sequanamedical.com/investors/shareholder-information .
  • The Company recommends the holders of its securities to use e-mail for all communications with the Company regarding the Annual and Extraordinary General Meetings of Shareholders.

Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality

Retrieved on: 
星期四, 五月 2, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, GV, Harvard University, Cancer, Genetics, Cell, Broad Institute, Survival, GV (company), Drug resistance, Growth, Overload, Oncogene, Patient, Neoplasm, NIBR, Investment, MIT, Pharmaceutical industry

Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.

Key Points: 
  • Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.
  • “Our activation lethality platform offers the potential for new cancer medicines that are effective on their own while also combating the emergence of resistance to classic targeted therapies.
  • Delphia integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality.
  • Through its activation lethality platform, Delphia is advancing a pipeline of first-in-class cancer medicines that aim to better control oncogenic pathways.

Axe and Driveline Baseball Unveil Power Trainer: Designed to Unlock Hitter Potential

Retrieved on: 
星期四, 四月 11, 2024
Mechanics, Axe, Partnership, Power, Engineering, Overload, Koko (gorilla), GM, MOI, Athlete, Knowledge, Sports equipment

KENT, Wash., April 11, 2024 /PRNewswire/ -- Baseball training innovators Axe and Driveline Baseball have joined forces again to launch the Power Trainer.

Key Points: 
  • KENT, Wash., April 11, 2024 /PRNewswire/ -- Baseball training innovators Axe and Driveline Baseball have joined forces again to launch the Power Trainer.
  • Building on the success of their acclaimed Axe Speed Trainers, the Power Trainer represents another step forward in their collaborative effort.
  • The Power Trainer combines Axe's bat design and engineering expertise with Driveline Baseball's cutting-edge data and hitting knowledge.
  • "We are thrilled to partner again with Driveline Baseball to create a training bat unlike any other," says Jay Helmick, GM of Axe Bat.

Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

Retrieved on: 
星期三, 四月 3, 2024
Cardiorenal syndrome, Congestion, DSR, Brussels Stock Exchange, Liver disease, Associate, RED, Patient, NYHA, Mortality, Cancer, Fluid, Heart failure, European Journal, Diuretic, Overload, Syndrome, Yale University, Pharmaceutical industry

The publication can be accessed here .

Key Points: 
  • The publication can be accessed here .
  • Dr. Jeffrey Testani, Associate professor at Yale University and senior author of the publication commented: “Cardiorenal syndrome is a major clinical challenge in heart failure with a clear unmet need for therapies to effectively and durably address congestion and cardio-renal dysfunction.
  • Currently the mainstay of therapy for sodium avidity and congestion are the loop diuretics, which actually worsen sodium avidity and cardiorenal syndrome.
  • Diuretic-resistant heart failure and cardiorneal syndrome are large and growing markets both in the US and rest of world, with the clear need for novel treatments that can improve clinical outcomes beyond loop diuretics.

Sequana Medical announces 2023 Full Year Results and 2024 Outlook

Retrieved on: 
星期四, 三月 28, 2024
Cardiorenal syndrome, Cirrhosis, Partner, Congestion, American Medical Association, Ascites, DSR, Brussels Stock Exchange, Liver disease, RED, Patient, Peritoneal dialysis, 2.0, Mouse, Sheep, Cancer, Heart, Heart failure, PMA, US FDA, Safety, File, CPT9, Overload, Catheter, ISO, THT, FDA, Animal, Pharmaceutical industry

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Securing PMA approval is a major value inflection point and the team is navigating through the approval process.

Key Points: 
  • Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Securing PMA approval is a major value inflection point and the team is navigating through the approval process.
  • Furthermore, the alfapump can benefit from attractive pricing and leverage its FDA breakthrough device designation to enhance its reimbursement position.
  • Following this equity placement, the €3.0 million convertible loan agreement entered in February 2024 by Partners in Equity and Rosetta Capital will be mandatorily converted into new shares.
  • A day-100 meeting is scheduled with the FDA on April 9th 2024.

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

Retrieved on: 
星期二, 三月 26, 2024
Brussels Stock Exchange, Exercise, Liver disease, Finance Secretary (India), Cancer, Disclosure, Heart failure, Overload, Consultant, Security (finance)

Ghent, Belgium, 26 March 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of the private placement of new shares that was announced and priced on 20 March 2024, with pricing announced on 21 March 2024, by means of a private placement through an accelerated bookbuilding procedure of new shares, the Company's share capital has increased on 25 March 2024 from EUR 2,926,295.90 to EUR 3,720,562.60 and the number of issued and outstanding shares has increased from 28,242,753 to 35,909,420 shares, through the issuance of a total of 7,666,667 new shares.

Key Points: 
  • Ghent, Belgium, 26 March 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of the private placement of new shares that was announced and priced on 20 March 2024, with pricing announced on 21 March 2024, by means of a private placement through an accelerated bookbuilding procedure of new shares, the Company's share capital has increased on 25 March 2024 from EUR 2,926,295.90 to EUR 3,720,562.60 and the number of issued and outstanding shares has increased from 28,242,753 to 35,909,420 shares, through the issuance of a total of 7,666,667 new shares.
  • The total current number of outstanding subscription rights amounts to 5,032,452, which entitles their holders (if exercised) to subscribe to 4,792,765 new shares with voting rights in total, namely:
    up to 261,895 new shares can be issued upon the exercise of 90,780 share options that are still outstanding under the 'Executive Share Options' plan for staff members and consultants of the Company, entitling the holder thereof to acquire ca.
  • upon the exercise of 10 warrants (each warrant having the form of a subscription right) that are still outstanding that have been issued by the extraordinary shareholders meeting of 27 May 2022 (the "Bootstrap Warrants");
    up to 161,404 new shares can be issued to Kreos Capital VII Aggregator SCSp.
  • upon the exercise of 875,000 warrants (each warrant having the form of a subscription right) that are still outstanding that have been issued by the extraordinary shareholders meeting of 10 February 2023 (the "Kreos Warrants")1; and
    This announcement is made in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy

Retrieved on: 
星期一, 三月 25, 2024
Cardiorenal syndrome, Congestion, Myocardial infarction, DSR, Brussels Stock Exchange, Liver disease, Partnership, RED, Patient, 2.0, Blood urea nitrogen, Cancer, Fluid, Heart, Heart failure, Furosemide, EGFR, Safety, DSMB, Overload, Hyponatremia, Hypertension, Pharmaceutical industry

These final data support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome.

Key Points: 
  • These final data support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome.
  • Unlike loop diuretics which, on average, have a negative impact on renal function and diuretic response, DSR has again demonstrated its potential to restore renal health and control of volume status.
  • Dramatic improvement in diuretic response and stable kidney function: During the four-week DSR treatment period, all three patients maintained euvolemia without the need of loop diuretics.
  • In January 2024, the independent DSMB approved the start of the randomized MOJAVE cohort following review of the safety data reported from the non-randomized cohort.

SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT

Retrieved on: 
星期四, 三月 21, 2024
Cardiorenal syndrome, EUR, Partner, DSR, Offering, Liver disease, Ketel One, KBC, Patient, 2.0, Cancer, Quality management system, AMERICA, Prospectus, Heart failure, EQT, LSP, PMA, US FDA, NASH, Overload, THT, USD, FDA, Security (finance)

This is an exciting time for Sequana Medical as the US FDA's review of our alfapump® PMA filing progresses and we continue our preparations for US commercial launch.

Key Points: 
  • This is an exciting time for Sequana Medical as the US FDA's review of our alfapump® PMA filing progresses and we continue our preparations for US commercial launch.
  • We look forward to continuing our track record of meeting our corporate milestones and driving Sequana Medical forward."
  • (ii)   Finalizing the North American pivotal study in recurrent and refractory liver ascites (POSEIDON) towards secondary endpoint readout planned for Q2 2024.
  • As announced in February 2024, the Company entered into an unsecured and subordinated convertible loan agreement with Partners in Equity and Rosetta Capital for an aggregate principal amount of EUR 3.0 million.

SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND PROVIDES TRADING UPDATE

Retrieved on: 
星期三, 三月 20, 2024
EUR, Partner, Tax, DSR, Offering, Liver disease, FY, Ketel One, KBC, International, Committee, Financial services, 2.0, Cancer, Quality management system, AMERICA, Prospectus, Heart failure, FSMA, Person, European, EQT, LSP, PMA, US FDA, Overload, Stock, Marketing, Transaction, Security (finance)

(ii)   Finalizing the North American pivotal study in recurrent and refractory liver ascites (POSEIDON) towards secondary endpoint readout planned for Q2 2024.

Key Points: 
  • (ii)   Finalizing the North American pivotal study in recurrent and refractory liver ascites (POSEIDON) towards secondary endpoint readout planned for Q2 2024.
  • The Offering shall be structured as a private placement of new shares via an accelerated bookbuilding, which will commence immediately.
  • Trading in Sequana Medical shares on the regulated market of Euronext Brussels will be suspended during the bookbuilding period.
  • Trading in the shares is expected to resume following the publication of the results of the Offering.

Visa Brings Convenience and Control to Booming Subscription Economy

Retrieved on: 
星期三, 四月 3, 2024
Personal Finance, Payments, Finance, Professional Services, Technology, Apps, Applications, Fintech, Digital Cash Management, Digital Assets, Overload, Food

Recognizing this, Visa (NYSE: V), a world leader in digital payments, today announced the launch of Subscription Manager, a new, all-in-one service for financial institutions to provide Visa cardholders with a simple, convenient way to track their subscriptions, all from the palm of their hands.

Key Points: 
  • Recognizing this, Visa (NYSE: V), a world leader in digital payments, today announced the launch of Subscription Manager, a new, all-in-one service for financial institutions to provide Visa cardholders with a simple, convenient way to track their subscriptions, all from the palm of their hands.
  • In the era of subscription overload, consumers are grappling with the complexities of managing multiple subscriptions across a web of apps.
  • Navigating through each platform’s unique terms can potentially lead to unnoticed charges, even after a subscription is cancelled.
  • For more information on this, as well as Visa's issuing solutions and other value-added services for businesses, please visit the Visa Developer Center .